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Abstract: Heterometallic drugs are emerging as a great 
alternative to conventional metallodrugs. The careful selection of 
the different metallic fragment makes it possible to enhance, not 
only the therapeutic potential by a synergy effect, but also the 
incorporation of key features like traceability. Drugs that 
integrate traceability and therapy in one system are known as 
theranostic agents. Among cancer research, theranostic agents 
are becoming increasingly important. They deliver crucial 
information regarding their biological interplay that can be 
ultimately used for the optimization process. The well 
established therapeutic potential of PtII, RuII and AuI based drugs, 
combined with the outstanding optical properties of d6 transition 
metal complexes grant the delivery of traceable metallodrugs. 
These species can be easily fine-tuned through modifications of 
their respective ligands to deliver a new generation of drugs. 
Introduction 
Barnet Rosenberg discovered that cisplatin possessed a potent 
chemotherapeutic action in 1965,[1] and later in 1978, cisplatin 
was approved by the FDA as treatment for testicular and 
advanced ovarian and bladder cancer. Since then, research into 
the mode of action of cisplatin and second generation of 
platinum based drugs (oxaliplatin and carboplatin) have 
encouraged many investigations, Figure 1.[2] Great efforts have 
been devoted to improve their efficiency while decreasing their 
secondary effects, that basically arise from their indiscriminate 
attack on all rapidly dividing cells.[3] Despite that, it is well 
accepted that cisplatin opened the door to study other transition 
metal complexes for the treatment of cancer.[4] Nowadays, 
ruthenium and gold complexes together with platinum-based 
drugs appear to be leading the research into the development of 
novel metallodrugs.[5] In fact, complexes derived from those 
metals such as NAMI-A, KP1019 and Auranofin reached 
different clinical trial phases for diverse cancer diseases (Figure 
1). In many cases, the lack of other effective treatments forces 
the extensive use of platinum drugs leading to drug resistance. 
Therefore, it is expected that the introduction of additional 
metallodrugs as standard treatments, would help to overcome 
such increase of the platinum drug resistance and to deal 






Figure 1. Example of metallodrugs approved by the FDA and at the stage of 
clinical trials. 
One of the major drawbacks in the development of advanced 
medicines is the lack of knowledge of their biological interplay. 
Gaining such information is crucial for the optimization of the 
drugs that will eventually endow specificity and effectiveness 
improving considerably the society wellbeing. Thus, the concept 
of theranostic agents has emerged as a revolution among the 
medical community. Theranosis involves diagnostic and 
therapeutic functions in one combined system, allowing 
diagnosis, therapy, and monitoring of therapeutic response at 
the same time, Figure 2.[6] For the diagnostic and monitoring 
function it is required the use of noninvasive imaging modalities. 
Among them, there are different techniques such as Position 
Emission Tomography (PET), Single Photon Emission Computer 
Tomography (SPECT), Computed Tomography (CT), Magnetic 
Resonance Imaging (MRI) or fluorescence microscopy that can 
be used. However, the different strengths and weaknesses 
displayed by each modality in terms of tissue penetration, 
resolution or applicability, make sometimes difficult to select 
one.[7] Thus, from our point of view, after considering the high 
cost of some of the techniques (MRI, CT, PET and SPECT) 
together with the necessity of using radionuclides or isotopes 
(MRI, PET and SPECT) in others, fluorescence microscopy 
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Figure 2. Pictogram describing the different possibility for theranostic agents. 
Fluorescence microscopy imaging is a powerful technique that 
can be performed on live cells.[8] It has various advantages 
including sensitivity, real-time visualization or non-ionization 
safety, which make the delivery of novel optical probes very 
appealing. The sub-micro molar detection of fluorophores and 
the possibility of collecting multiple wavelengths simultaneously 
allow the use of specific organelle stains that considerably 
facilitates the assessment of the biodistribution. However, an 
obvious limitation would be having optical probes that emit within 
the detectable wavelength window, i.e. in the UV - NIR range, 
the latter being preferable because of the greater depth tissue 
penetration. NIR-II organic fluorophores have emerged as one of 
the alternatives to circumvent such limitation. These 
fluorophores emit at the second near- IR region between 1000 
and 1700 nm, offering deep light penetration and low auto-
fluorescence.[9] Some examples of those combined with 
platinum based metallacycles have provided very promising 
metalo-based theranostic platforms for efficient imaging and 
therapy.[10] Alternatively, metal-based optical probes are also 
ideal candidates as most of them displayed a phosphorescent 
emission. In particular, complexes derived from d6 metal 
complexes have been recently used as optical probes for cell 
imaging.[11] Their emission properties, easily tunable by simple 
functionalization of the coordinated ligands, afford a wide range 
of possibilities ranging from blue to red emitters.[12] Moreover, 
their excited state lifetimes, much longer to those of endogenous 
fluorophores (0.1-7 ns)[13] facilitate the use of time-gated 
techniques that eliminate autofluorescence of the sample and 
renders images with greater signal-to-noise ratio. [14]  
Taking into account the advantages displayed by metallic 
complexes in cellular imaging, and the importance of cellular 
tracking for the development of novel and more effective 
metallodrugs, the idea of combining a metallic bioprobe with a 
luminescent complex to function as tracking tag is very 
appealing. By this means, the concept of heterometallic 
theranostic agents arises, and every day is gathering more 
supporters among the research community. Although in early 
2018 our research group published a concept article on 
heterobimetallic probes as theranostic agents,[15] the increasing 
amount of research published since them, makes this subject 
worthy of an update. Therefore, in this concept article, we gather 
the reported examples dealing with heterometallic complexes 
that have shown promising properties as theranostic agents. We 
will focus on species combining luminescent d6 metal complexes 
with potential bioactive metallodrugs derived from PtII, RuII and 
AuI, as complexes derived from those metals have already 
shown their great projection in therapy. Finally, we will highlight 
the strengths of heterometallic theranostic probes and we will 
discuss the future challenges that need to be addressed in order 
to eventually deliver a heterobimetallic theranostic probe into 
clinical trials. 
Heterometallic metallodrugs 
Among the published reports dealing with the search of novel 
metallodrugs, can be found examples of heterometallic 
complexes based on the hypothesis that combination of two 
cytotoxic metals may enhance the cytotoxic potential as well as 
overcoming drug resistance.[16] In fact, in most of the cases this 
idea is validated, and polynuclear complexes turned to be potent 
inhibitors off cancer cells with a significant improvement 
compared with their mononuclear parent species.[17] Thus, 
Figure 3 illustrates some examples combining fragments derived 
from RuII, PtII, AuI, TiIV, CuII, AgI, IrIII or FeII, some of them with 
analogous chemical structures to that of RAPTA-T, cisplatin, 
auranofin, titanocene of ferrocene, have been combined to 
deliver species with enriched cytotoxicity towards different lines 
of cancer cells (1-7).[18] Among them, there are specific 
examples that bring together bioactive species with well-known 















This article is protected by copyright. All rights reserved.
CONCEPT          
3 
 
Figure 3. Heterometallic bioprobes including specific examples with potential 
application in bioimaging. 
However, even though they have demonstrated to be cytotoxic 
and to interact with a specific biological target, no studies 
dealing with their cell biodistribution were performed.[19] 
Therefore, there is no assurance that the molecule reaches the 
assumed target in a cellular environment. 
 
As previously observed optical theranostic probes can be easily 
tracked inside cells by fluorescence microscopy. Thus, this 
visualization technique in combination with a theranostic agent 
make possible to demonstrate that the probes are able to reach 
the specific organelle or biological target where the therapeutic 
action is undertaken. Without such information, it is very difficult 
to ensure that the probe will have a specific action mechanism. 
There are probes that due to their chemical structure, for 
instance, the presence of planar aromatic ligands, or specific 
metal centers such as AuI, are known to selectively interact with 
DNA or with enzymes like thioredoxin reductase (TrxR) 
respectively.[20,21] However, their biological interplay can be very 
different if the probes are not able to reach their assumed 
biological targets. Therefore, the approach towards the 
development of a new drug when it comes to deliver theranostic 
probes is completely different. The interaction with the biological 
target is studied after knowing the information of the inner 
cellular biodistribution by visualization techniques. 
Heterometallic ReIAuI bioprobes for 
theranostic applications 
The first heterometallic d6-d10 emissive probes designed for 
tracking and therapy applications was developed by our 
research group in 2014.[22] Thus, a series of luminescent ReIAuI 
derivatives were described by the combination of a well-known 
emissive ReI core, fac-{Re(bipy)(CO)3}, and a potential bioactive 
AuI species of the type C-Au-P, Figure 4, complexes 8-11. Both 
fragments were connected through an alkynyl pyridine/imidazole 
derivative by a stepwise synthetic procedure. The excellent 
photophysical properties of the ReI fragment allowed tracking 
the biodistribution of the probes in lung cancer A549 cells. 
Moreover, the analysis of the cytotoxic activity of each 
monometallic fragment disclosed IC50 values over 120 µM 
indicating that the therapeutic potential was exclusively due to 
the AuI fragment, being the role of the ReI fragment relegated to 
visualization purposes, see table b in Figure 4. Fluorescence 
microscopy showed a different biodistribution driven by the 
loading concentration of the probes. Thus, localization of the 
probes shifted from the cytoplasm, possibly in the mitochondria, 
to the nucleus and nucleolus upon increasing the loading 
concentration over the IC50.[22] 
Since them related examples have been published combining 
ReIAuI metal centers in order to optimize the metallic 
combination. Analogous heterometallic probes 12-17, preserving 
the emissive ReI core and exploring diverse AuI coordination 
sphere (P-Au-P, or P-Au-Cl) were described.[23] However, their 
antiproliferative potential towards A549 cells were lower than in 
the previous examples 8-11. The overall cytotoxicity resulted to 
follow the trend (C-Au-P) > (P-Au-P) > (P-Au-Cl) for the AuI 
fragment. A similar biodistribution pattern was observed for 16 
and 17, with a non-uniform cytoplasmic distribution as well as 
nuclear permeation, and further studies revealed DNA 
interaction and passive diffusion as the entrance pathway.[23] 
Additional heterometallic probes, where the typical ReI 
luminescent core was this time modified to fac-{Re(NHC)(CO)3}, 
were described (species 18-20 in Figure 4a).[24] These species 
had a blue shifted emission (λem < 500 nm) to that published so 
far with the diimine-ReI system, leading to poorer systems for 
bioimaging applications. In fact, only complexes 18 and 19 could 
be followed by fluorescence microscopy. Their antiproliferative 
potential was similar to that of species 8 to 11, indicating again 
the high dependence on the nature of the AuI coordination 
sphere to reveal the cytotoxicity. Moreover, these species 
showed an increment of the cytotoxicity upon irradiation, which 
is encouraging to proceed towards photodynamic therapy 
applications, see footnote on the table of Figure 4.[24] 
Alternative ReIAuI probes, where the bioactive fragment was 
introduced within the emissive ReI core, were also reported, 
species 21-25 in Figure 4.[25] This is a new approach to those 
described so far. Any changes on the bioactive fragment could 
be monitored by fluorescence techniques, giving the information 
of the precise moment of interaction with the biological target. In 
fact, we demonstrated that monometallic ReI and heterometallic 
ReIAuI species as well as a substitution of gold ancillary ligand in 
ReIAuI lead to modifications on the emission maxima. Overall it 
was revealed that these species had selectivity and higher 
cytotoxicity towards cervix cancer HeLa cells than in the case of 
A549 cells at long incubation times (72h). Fluorescence 
microscopy showed that the complexes were biodistributed 
differently in both cell lines, being this the trigger for the different 
effect. Thus, whereas complexes interact with the cellular 
membrane of HeLa cells, they were randomly distributed in 
A549 cells, Figure 4c, complex 22.[25] 
In summary, the bimetallic ReIAuI library, developed entirely by 
our research group, have outlined several guidelines to be able 
to deliver optimized optical theranostic agents containing these 
metal centers. The low biological media solubility displayed by 
some species can be overcome by either substitution of the gold 
ancillary ligand or removing the chloride of the rhenium core for 
a neutral donor ligand. Typically, substitution of the halide ligand 
in the Re(I) core for a N-donor ligand renders greater solubility 
as the character of the ReI core changes from neutral to cationic. 
Moreover, extending the aromaticity or electron movement along 
the chelated (N^N) ligand improves the light depth penetration of 
the probe. Moreover, a careful selection of the gold ancillary 
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Figure 4. a) Reported examples of Re(I)/Au(I) theranostic agents. b) IC50 data of complexes 8-25 in different tumor cellular lines and different conditions. c) 
Biodistribution profiles of 16, 18 and 22 in AA549 cells. [19] - Reproduced by permission of The Royal Society of Chemistry. Adapted with permission from ref [20]. 
Copyright (2017), ref [21]. Copyright (2018), ref [22]. Copyright (2020), American Chemical Society.  
  
Heterometallic  RuII-based bioprobes for 
theranostic applications 
In 2015, the first examples dealing a heterometallic emissive RuII 
and a bioactive AuI species was described by the hand of 
Hemmert and Gornitzka.[26] They funtionalized the typical 
emissive [Ru(bipy)2(N^N)]2+ core, where N^N represent a diimine 
ligand, with an imidazole derivative that later was used as linker 
for the AuI fragment, Figure 5. Thus, the correspondent gold-
NHC complex obtained was expected to deliver high cytotoxicity 
as many other gold-NHC compounds had demonstrated.[27] 
However, even though complexes 26-28 presented certain 
bioactivity, they did not improve that given by Sorafenib, a 
commercial available drug used as reference compound. 
Despite of that, observation of luminescent properties revealed 
that the presence of AuI fragment do not interfere with emission 
of the RuII fragment but increased its quantum yield, making 
them very appealing for bioimaging applications. Complex 27 
localized in the cytoplasm, mainly in the peripheral area of the 
nuclei of liver cancer cells Hep3B, Figure 5. Changes in the 
emission maxima wavelength observed in time dependent 
fluorescence microscopy experiments suggested that the gold 
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Figure 5. IC50 data of complexes 26-28 in human hepatocellular carcinoma 
cell (Hep3B). Cellular biodistribution of 27. Adapted with permission from ref 
[23]. Copyright (2015) American Chemical Society 
Thereafter similar heterobimetallic probes were reported by 
Casini, Bodio and coworkers.[28] This time the gold coordination 
sphere was modified to have a similar structure to that of 
auranofin in order to increase as much as possible its 
therapeutic potential. Thus, the bifunctional diimine ligand used 
as linker between both metallic fragments has a phosphorus 
donor atom able to coordinate the AuI center. Moreover, the gold 
coordination sphere was completed with a thioglucose, Figure 6. 
Additional modifications on the optical RuII properties were made 
with the introduction of a 2,2-dipyridyl amine instead of the 
previous bipyridine ligand. As expected, RuIIAuI complexes 
containing the thioglucose (31, 32) instead of the chloride (29, 
30) had greater cytotoxicity, corroborating the strong influence of 
the gold ancillary ligands on the therapeutic potential. All of them 
are emissive, 29 and 31 being the stronger emitters. Moreover, 
they permeated the cell via an active transport mechanism. Both 
thioglucose derivatives showed different cellular biodistribution. 
Whereas 31 accumulated in the cytoplasm, 32 was located in 
the nucleus and organelles therein, outlining that, not only the 
bioactive AuI fragment participates on the biodistribution, but 
also the luminescent RuII core is implicated. 
 
Figure 6. IC50 data of complexes 29-32 lung cancer cells (A549). Cellular 
biodistribution 31 (upper picture) and 32 (lower picture). Complexes in pink, 
DAPI (nuclear dye) in blue. Adapted with permission from ref [25]. Copyright 
(2016) American Chemical Society 
Alternatively to the RuIIAuI combination, an example including a 
PtII based fragment with a similar structure to that of cisplatin 
has been reported. Thus, Thomas, Smythe and coworkers 
described a RuIIPtII complex that can be used as a DNA light 
switch drug, Figure 7a.[29] The authors rely on both, the well-
known DNA interaction of cisplatin different to that of bisimine 
RuII cores, and the luminescence enhancement observed for 
latter in presence of DNA, Figure 7b. Eventually, it was found 
that the heterobimetallic complex 33 had lower cytotoxicity than 
cisplatin in ovarian cancer cell lines A2780, but no significant 
change was seen towards platinum resistant A2780CIS, 
suggesting that the platinum resistance was not governed by the 
DNA interaction mode. Optical properties of the complex allowed 
to visualize structural changes on the interaction mode of the 
complex with DNA, monitoring the switch from intercalation to 
groove binding as well as investigating the cell death timing. 
Thus, live-cell fluorescence microscopy suggested a fast cell 
death mechanism though oncosis, characterized by loss of 
cytoplasmic volume control among other features, see Figure 7c.  
 
 
Figura 7. a) Depiction of 33. b) Increase in luminescence of 33 on addition of 
calf thymus DNA (λex = 450 nm). Inset: Derived binding curve from these 
data. c) Time dependent cellular uptake of 33 into A2780. Images show 
luminescence arising from MLCT superimposed on phase contrast 
micrographs. Arrows indicate examples of oncotic cell swelling. Adapted with 
permission from ref [26]. Copyright (2019) American Chemical Society 
Heterometallic IrIII- based bioprobes for 
theranostic applications 
IrIII complexes bearing cyclometallated ligands exhibit well-
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cellular imaging,[30] as well as, a great stability in biological 
media. For this reason, they are excellent candidates to be used 
as emissive tags of therapeutic drugs. In addition, many 
cyclometallated IrIII species have shown to be active as 
photosensitizers in photodynamic therapy,[31] opening the door to 
the design of multimodal species. Moreover, cyclometallated IrIII 
compounds of the type [Ir(N^C)2(N^N)]0/+, where N^C represent 
an orthometallated ligand, display general features such as an 
easy synthesis and air and moisture stability, reinforcing their 
medicinal potential as part of a heterometallic theranostic agent. 
In 2014, a hetero-binuclear IrIIIRuII complex, 34, was developed 
by Kim, Patra and co-workers, Figure 8.[32] The idea behind their 
design was to gain insight on drugs that trigger autophagy, as 
these drugs can kill cells resistant to apoptosis. For that, the 
authors relayed on synergistic interaction of the multimetallic 
framework combined with polypyridyl ligands, which are known 
to enhance the cellular uptake.[33] In fact, complex 34 was highly 
cytotoxic towards cisplatin resistance MCF7 cancer cells as well 
as in other cell types. The formation of acidic vacuoles in MCF7 
cells in presence of 34 was key for suggesting its capacity to 
induce autophagy, Figure 8. Therefore, this was the first 
example of trackable heterodinuclear IrIIIRuII complex with 
capacity to produce autophagy. 
 
 
Figure 8. Chemical structure of 34 and related cytotoxicity in MCF7 and PC3 
cell lines. Overlapped fluorescence microscopy images (a) acridine orange 
stained and (b) acridine orange stained and complex 34. 
Recently, our research group in collaboration with that of 
Metzler-Nolte also contributed to the development of 
heterometallic IrIII-based bioprobes for theranostic applications. 
We synthetized diverse IrIIIAuI peptide bioconjugates, complexes 
35 and 36, Figure 9, with the idea that the peptide will assist to 
improve water solubility and facilities cell recognition of the 
probe.[34] The introduction of the gold fragment was achieved via 
coordination through different groups (alkynyl or sulfur) present 
in the peptides. We demonstrated a lysosomal accumulation for 
all the complexes. However, only the species 36, which contains 
a cysteine, displays cytotoxic activity towards A459 cell line. 
Interestingly, this behavior suggested that the strength of the Au-
ligand bond could play a crucial role. While Au-S(cysteine) bond 
was more readily cleaved in a biological environment, the Au-
C(triazole) bond was presumably more stable, and thus gold 
fragment might remain linked to the peptide, which is trapped in 
the lysosome, preventing cytotoxicity [35]. 
Figure 9. Chemical structures of compounds 35 and 36 and fluorescence 
microscopy images of a colocalization experiment of 35 and 36 with 
LysoTracker-red in A549 cells. 
Unconventional heterometallic based 
bioprobes  
Apart from the heterometallic complexes described so far, 
containing two metallic fragments well differentiated for either 
bioimaging or therapy, there are analogous complexes where no 
specific therapy based fragment is present. Instead, a 
completely different metallic fragment to the conventional 
cisplatin, auranofin or RAPTA-T is included. Therefore, in 
principle, it is not possible to assign the bioactivity to one of 
the metal fragments itself, unless one of them clearly 
displays cytotoxicity upon irradiation. For the other bimetallic 
species, the combination of both fragments and the 
subsequent synergy effect are governing their therapeutic 
effect. Several examples can be found for different bimetallic 
species, IrIIIRuI and ReIRuII. Thus, in 2014, two research groups, 
one of them headed by X. Peng and the other one by J. A. 
Thomas, reported simultaneously the first examples of these 
unconventional heterometallic based bioprobes.[36,37] Both 
examples dealt with heterodinuclear IrIIIRuII complexes. 
Surprisingly, the studies demonstrated significant DNA/rRNA–
binding affinities for the different probes. In one hand, Peng and 
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showed a dual-emissive response in the green and orange 
region (523 nm and 615 nm). Colocalization experiments 
confirmed the nucleolar localization of the complex, as well as, 
suggested a high binding affinity of the complex towards RNA, 
see Figure 10. 
 
 
Figure 10. Chemical structure of 37 a) Co-staining of 37 with SYTO RNA-
Select dye. Left: RNA-Select dye (green channel); Middle: 37 (red channel); 
Right: merged image. b) Colocalization of 37 and Hochest33258. Left, 
Hochest33258 (blue channel); Middle, 37 (red channel); Right, merged image. 
Scale bar: 20 μm.  
On the other hand, the group headed by J. A. Thomas prepared 
two new luminescent dinuclear IrIIIRuII complexes, 38 and 39.[37] 
These compounds displayed good water solubility and affinity for 
DNA-binding. Additionally, cellular studies demonstrated nuclear 
uptake, which was enhanced for the fluorinated-derivative 39, 
targeting the nucleus more rapidly than the non-fluorinated, 
complex 38. 
 
Figure 11. Chemical structure of complexes 38 and 39 and isolated HeLa 
chromosomes stained with 38, in metaphase spreads. 
In a similar manner, Chao et al.[38] synthetized an additional 
IrIIIRuI complex, this time as a bifunctional agent for 
photoactivated chemotherapy and photodynamic therapy, Figure 
12. The idea was to use the IrIII fragment to target mitochondria 
meanwhile using the RuII species to induce the mtDNA damage. 
In fact, complex 40, exhibited antitumor activity towards 
cisplatin-resistant cancer cells and specifically accumulates in 
mitochondria. Furthermore, complex 40 could generate 1O2 only 
under step-wise irradiation, after irradiating at 450 nm and then 
at 405 nm, Figure 12. Additionally, the heterobimetallic complex 
was able to induce mitochondrial dysfunction, leading to the loss 
of mitochondrial membrane potential (MMP), promoting an 
apoptotic cell-death pathway.  
Figure 12. a) Chemical structure of complex 40. b) Cytotoxicity in lung cancer 
cells A549, in cisplatin resistant lung cancer cells A549R. c) study of cell 
apoptosis by Annexin V-FITC/PI co-staining assay in A549R cells after 
complex 40 treatment with or without irradiation. 
Alternative to the development of IrIIIRuII probes, J. A. Thomas 
and C. Smythe also pioneered the work on the bimetallic ReIRuII 
complexes, where the ruthenium fragment differs from that of 
the typical RAPTA-T derivative, used so far in the conventional 
heterobimetallic theranostic examples containing a RuII fragment 
for therapy. The first work entailed a metallomacrocycle, species 
containing two [Ru(bipy)2(N^N)]2+ units, where the N^N was a 
quaterpyridine derivative used as bridge ligand between ReI and 
RuII metallic centers, Figure 13. [39] Complex 41 showed different 
cell localization depending on the experimental method used, i.e. 
fixed or life cell studies. Thus, 41 mainly localized in the nuclear 
membrane and the endoplasmatic reticulum (ER) of fixed MCF7 
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localization and morphological changes were observed. At the 
beginning of the experiment, only plasma membrane was 
stained. Then, nuclear and nucleolar localization was observed. 
Eventually a general nuclear membrane and other organelle 
membranes as well as ER were stained followed by a gross cell 
swelling that leaded to cell death. Alternatively, the cells 
incubated with 41 in the dark kept normal morphology indicating 
that the RuIIReI complex functioned as a potent photosensitizer 
though ROS generation. 
 
 
Figure 13. Chemical structure of 41 and time dependent fluorescence 
microscopy images of 41 incubated with live MCF7 cells. 
Recently, the same research group also developed novel ReIRuII 
complexes linked by simple dipyridyl alkane ligands.[40] This time 
the typical tris-bisimine RuII structure was substituted for a 
tripodal tris(1pyrazolyl)methane (tpm), a dipyrido[3,2-a:2’,3’-
c]phenazine (dppz) and a dipyridyl alkane ligand that was used 
as connector between the RuII and ReI fragments, see Figure 14. 
The nature of the dipyridyl linkers affects the biodistribution as 
well as photostability. Thus, 42 showed low photostability and 
localized in the nucleus of ovarian cancer cell line A2780, 
whereas 43 cells has negligible photobleaching and its 
localization is concentration dependent, going from cytosol to 
the nucleus upon increasing the loading. Regarding the 
cytotoxicity, only complex 43 presented similar antiproliferative 
activity to that of cisplatin. Both complexes bind to DNA with 
similar affinities, however, it seems clear that the nature of the 
linkers is affecting their final bioactivity potential. 
Figure 14. a) Chemical structure of 42 and 43. b) UV-visible study of DNA 
interaction with 43. c) Image of a colocalization experiment of 43 with H33342, 
a nuclear commercial available dye. Adapted with permission from ref [36]. 
Copyright (2020) American Chemical Society. 
STRENGTHS, FUTURE CHALLENGES OF 
HETEROMETALLIC THERANOSTIC PROBES AND 
CONCUSIONS 
The lack of understanding of the mechanism of action of a drug 
is one of the main handicaps for not being able to succeed in the 
delivery of effective drugs that can pass to clinical trials. 
Therefore, tracking the drug at every stage gives crucial 
information that can be used for a better drug design. Opting for 
a d6 metallic fragment over an organic chromophore for the 
imaging process offers clear advantages on the quality and 
resolution of the images, overcoming typical problems of organic 
chromophores specially those related with photostability. 
Consequently, the enhanced relative photostability of transition 
metal complexes enables their application in long-term 
observation as well as in dynamic monitoring of living biological 
systems. Even though sometimes the synthetic pathway for a 
bimetallic theranostic agent might seem more complicated than 
that for organic-based derivatives, there are three main synthetic 
strategies that can be used to easy their preparation: a) 
synthesis separately of each metallic fragment followed by 
coupling step, b) design of a bifunctional chelate ligand to 
selectively bind each metallic fragment and c) a stepwise 
synthesis.  
On the therapeutic aspect, metals are endowed with unique 
properties not found in conventional carbon-based drugs. 
Therefore, exploration of metal -based drugs should lead to new 
therapies able to reduce side effect, increase the spectrum 
activity and, more importantly, overcoming drug resistance 
already seen by conventional drugs. The examples reported 
herein, heterometallic theranostic optical probes, are attracting a 
growing interest especially in the last years. However, research 
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developed systems, although being very promising, are still far 
from the clinical stage. Finding a therapeutic synergy effect is 
feasible and it would enhance their potential if the emissive 
metallic tag renders additional cytotoxicity. Apart from features 
such as the optima solubility and stability, for drug administration, 
or the increased therapeutic potential, for reaching less 
conventional treatable cancers, selectivity of the drugs remains 
as one of the main challenges to deliver efficient anticancer 
medicines. In our opinion, achieving cancer cell selectivity and 
more specifically reaching the right biological target is crucial. 
Heterometallic optical theranostic agents can help to understand 
the biological interplay of the drug, facilitating the information 
gathering for its optimization. Therefore, constant and rigorous 
work into the development of heterometallic complexes is 
mandatory. Eventually, reaching the stage of in vivo monitoring 
and evaluation of these metal-based theranostic agents would 
be a great step forward for their clinic translation.  
Alternatively, multimodal therapy combining chemotherapy, 
photodynamic therapy with optical imaging techniques seems 
achievable with heterometallic probes. The non-conventional 
heterometallic drugs are taking the lead in this category, but still 
there is a long way to cover. This appealing area of research will 
surely lead to new metallodrugs in the future, but for the moment 
only initial prototypes are developed. 
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Heterometallic drugs are evolving as a great alternative to conventional drugs. Combination of different metallic fragments enhances 
therapeutic potential and endows the drugs with traceability, delivering a new class of theranostic agents. The well-stablished 
therapeutic potential of PtII, RuII and AuI based drugs, and d6 transition metal complexes makes an excellent partnership for the 
development of novel traceable heterometallodrugs. 
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